Recently, low baseline LDH-ratio, absence of visceral metastasis other than soft-tissue/lung, high relative lymphocyte count (RLC) and high relative eosinophil count (REC) were shown to be associated with improved survival of melanoma patients receiving the PD-1 blocker pembrolizumab [6]. The gene discussed is PDCD1; the disease is melanoma.